Categories
Blood Cancer

Acalabrutinib in patients with CLL and MCL undergoing alloSCT [Video]

Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland comments on the administration of acalabrutinib after allogeneic stem cell transplantation (alloSCT) in patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Prof. Jurczak also comments on how the rapid advances in CAR-T cell therapies may impact this. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Blinatumomab as consolidation for adult B-ALL [Video]

Irene Urbino, MD, Città della Salute e della Scienza di Torino, Turin, Italy discusses the efficacy of blinatumomab given as consolidation in adults with B-cell precursor acute lymphoblastic leukemia (B-ALL). Dr Urbino describes how, in this real-world evidence study, patients with B-ALL were divided into three subgroups – those in first complete remission (CR1), those in second CR after chemotherapy-base salvage therapy (CR2), and those in overt relapse (R/R). The results of the study highlight that blinatumomab should preferably be used in consolidation rather than as salvage therapy in patients with B-ALL in first relapse. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Epigenetic mechanisms driving the progression of MDS to secondary AML [Video]

Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China talks on the various mechanisms which drive the progression of myelodysplastic syndromes (MDS) to secondary acute myeloid leukemia (AML). Dr Gill outlines the two most common mutational profiles seen in patients with MDS who progress to secondary AML – the accumulation of genes which confer a proliferative advantage and the acquisition of mutations in tumor suppressor genes. Dr Gill also comments on how the treatments patients with MDS receive may also contribute to the progression, for instance hypomethylating agents (HMAs) potentially inducing epigenetic changes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Inotuzumab ozogamicin for MRD-positive B-ALL [Video]

Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, discusses the results of a Phase II study investigating the use of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive (Ph+ALL) and negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) who are measurable residual disease (MRD)-positive. Whilst the study reported promising overall response rates (ORR), it did not meet its primary endpoint. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

TakeAim Leukemia: emavusertib as monotherapy or with azacitidine or venetoclax in R/R AML or MDS [Video]

Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the rationale and results of TakeAim Leukemia, a Phase I/IIa dose escalation and cohort expansion study evaluating the safety and clinical activity of the IRAK4 inhibitor emavusertib alone or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (NCT04278768). Overall, the agent showed a promising activity in this patient population, especially in patients with splicing mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Fixed-duration vs continuous therapy in CLL [Video]

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, compares defined duration versus continuous therapy in chronic lymphocytic leukemia (CLL), commenting on the possibility of finding biomarkers to define the length and intensity of treatment for each patient, and highlighting promising results from the HOVON-141/VISION trial (NCT03226301). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Working towards a cure in CML [Video]

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, reflects on the potential for a cure in patients with chronic myeloid leukemia (CML), highlighting treatment discontinuation in 20-25% of patients treated with a tyrosine kinase inhibitor (TKI). Future endeavors are focusing on increasing the percentage of patients with CML achieving prolonged remission. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Ongoing trials in AML and HR-MDS: ENHANCE, ENHANCE-2 and ENHANCE-3 [Video]

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses three ongoing studies investigating various treatment combinations in acute myeloid leukemia (AML) and high-risk (HR) myelodysplastic syndromes (MDS), including the ENHANCE study (NCT04313881), the ENHANCE-2 study (NCT04778397), and the ENHANCE-3 study (NCT05079230). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated AML patients [Video]

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated acute myeloid leukemia (AML) patients, highlighting the promising response rates and overall survival, as well as the future role of this combination in the treatment of these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Acalabrutinib vs ibrutinib in previously untreated high-risk CLL [Video]

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, outlines the key findings of the head-to-head comparison of acalabrutinib vs ibrutinib in the frontline treatment of high-risk chronic lymphocytic leukemia (CLL) (NCT02477696). Whilst the trial did not find a difference in progression-free survival (PFS) between the two BTK inhibitors, there was a significant reduction in atrial fibrillation in patients treated with acalabrutinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Treating patients with AML: how far have we come? [Video]

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the advances that have been made in treating patients with acute myeloid leukemia (AML). These include the introduction of 7+3 (cytarabine + daunorubicin) to the treatment armamentarium, as well as further understanding of the molecular features of disease, and the subsequent targeted therapies to treat specific disease subtypes. However, despite the added value of targeted therapies – there is still an important role of intensive chemotherapy in patients with AML. Prof. Mohty notes that CPX-351 is one important advancement that has been made in a chemotherapy treatment option for patients with AML. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

RIC vs MAC in MRD-positive & MRD-negative patients with AML [Video]

Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on the use of reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) in patients with acute myeloid leukemia (AML) who are measurable residual disease (MRD)-positive or MRD-negative. Whilst studies have suggested that MRD-positive patients should be treated with MAC, it is necessary to conduct a prospective study to determine the best conditioning regimen for MRD-negative patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.